AUTHOR=Zhen Changlin , Wu Xunxun , Zhang Jing , Liu Dan , Li Guoli , Yan Yongbo , He Xiuzhen , Miao Jiawei , Song Hongxia , Yan Yifan , Zhang Yonghui 

TITLE=Ganoderma lucidum polysaccharides attenuates pressure-overload-induced pathological cardiac hypertrophy

JOURNAL=Frontiers in Pharmacology

VOLUME=14

YEAR=2023

URL=https://www.frontiersin.org/journals/pharmacology/articles/10.3389/fphar.2023.1127123

DOI=10.3389/fphar.2023.1127123

ISSN=1663-9812

ABSTRACT=<p>Pathological cardiac hypertrophy is an important risk factor for cardiovascular disease. However, drug therapies that can reverse the maladaptive process and restore heart function are limited. <italic>Ganoderma lucidum</italic> polysaccharides (GLPs) are one of the main active components of <italic>G. lucidum</italic> (<italic>Ganoderma lucidum</italic>), and they have various pharmacological effects. GLPs have been used as Chinese medicine prescriptions for clinical treatment. In this study, cardiac hypertrophy was induced by transverse aortic constriction (TAC) in mice. We found that GLPs ameliorate Ang II-induced cardiomyocyte hypertrophy <italic>in vitro</italic> and attenuate pressure overload–induced cardiac hypertrophy <italic>in vivo</italic>. Further research indicated that GLPs attenuated the mRNA levels of hypertrophic and fibrotic markers to inhibit cardiac hypertrophy through the PPARγ/PGC-1α pathway. Overall, these results indicate that GLPs inhibit cardiac hypertrophy through downregulating key genes for hypertrophy and fibrosis and attenuate pressure overload-induced pathological cardiac hypertrophy by activating PPARγ. This study provides important theoretical support for the potential of using GLPs to treat pathological myocardial hypertrophy and heart failure.</p>